Journal articles

  1. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS. Nature Communications. 5:4715. PDF
  2. Lymphatic endothelial cells support tumor growth in breast cancer. Lee E, Pandey NB, Popel AS. Scientific Reports. 4:5853. PDF
  3. Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Lee E, Pandey NB, Popel AS. Clinical & Experimental Metastasis. 31(1):67-79. PDF
  4. Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Lee E, Lee SJ, Koskimaki JE, Han Z, Pandey NB, Popel AS. Scientific Reports. 4:7139. PDF
  5. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Lee E, Koskimaki JE, Pandey NB, Popel AS. Neoplasia. 15(2):112-24 (Cover Article). PDFCover_Neoplasia-2013
  6. Biomimetic on-a-chip platforms for studying cancer metastasis. Lee E, Song HG, Chen CS. Current Opinion in Chemical Engineering. 11:20-27. PDF
  7. Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. Lee E, Pandey NB, Popel AS. Expert Reviews in Molecular Medicine. 17:e3. PDF
  8. Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Lee E, Rosca EV, Pandey NB, Popel AS. International Journal of Biochemistry & Cell Biology. 43(12):1812-21. PDF
  9. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Lee E, Kim YS, Bae SM, Kim SK, Jin S, Chung SW, Lee M, Moon HT, Jeon OC, Park RW, Kim IS, Byun Y, Kim SY. International Journal of Cancer. 124(12):2755-65. PDF
  10. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. Fertig EJ*, Lee E*, Pandey NB, Popel AS. Scientific Reports. 5:12133. PDF
  11. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Koskimaki JE*, Lee E*, Chen W, Rivera CG, Rosca EV, Pandey NB, Popel AS. Angiogenesis. 16(1):159-70. PDF
  12. The Angiogenic Secretome in VEGF overexpressing Breast Cancer Xenografts. Dore-Savard L, Lee E, Kakkad S, Popel AS, Bhujwalla ZM. Scientific Reports. 6:39460. PDF
  13. Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model. Kim E, Lee E, Plummer C, Gil S, Popel AS, Pathak AP. Angiogenesis. 18(2):125-36. PDF
  14. Angiogenesis interactome and time course microarray data reveal the distinct activation patterns in endothelial cells. Chu LH, Lee E, Bader JS, Popel AS. PLoS One. 9(10):e110871. PDF
  15. Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro. Hassell BA, Goyal G, Lee E, Sontheimer-Phelps A, Levy O, Chen CS, Ingber DE. Cell Reports. 21(2):508-516 (Cover Article). PDFcover1
  16. Laminar flow downregulates Notch activity to promote lymphatic sprouting. Choi D, Park E, Jung E, Seong YJ, Yoo J, Lee E, Hong M, Lee S, Ishida H, Burford J, Peti-Peterdi J, Adams RH, Srikanth S, Gwack Y, Chen CS, Vogel HJ, Koh CJ, Wong AK, Hong YK. Journal of Clinical Investigation. 127(4):1225-1240. PDF
  17. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Koskimaki JE, Rosca EV, Rivera CG, Lee E, Chen W, Pandey NB, Popel AS. Translational Oncology. 5(2):92-7. PDF
  18. A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer. Rosca EV, Penet MF, Mori N, Koskimaki JE, Lee E, Pandey NB, Bhujwalla ZM, Popel AS. PLoS One. 9(11):e111901. PDF
  19. Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells. Bressler EM, Kim J, Shmueli RB, Mirando AC, Bazzazi H, Lee E, Popel AS, Pandey NB, Green JJ. Journal of Biomedical Materials Research A. 106(6):1753-1764. PDF

(*Equal contribution)


  1. Heparin conjugates and methods. Y Byun, ES Lee, O Jeon, SY Kim, RW Park,
    US Patent 8,088,753. PDF
  2. Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis-and lymphangiogenesis-dependent diseases. AS Popel, NB Pandey, E Lee, JJ Green, RB Shmueli, US Patent 9,802,984. PDF



%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close